Nasdaq:BBLG
Bone Biologics Corp
A clinical-stage biopharmaceutical company developing next-generation bone regeneration therapies to treat orthopedic conditions without current product revenue.
Key Metrics
Investment Thesis
Bull Case
Investors might consider BBLG if the company's pipeline achieves successful clinical trial readouts leading to FDA approval and eventual commercial sales of high-value bone regeneration products. The significant increase in cash reserves from $3.3M to $5.3M provides a runway to continue R&D without immediate dilution, while the lack of current revenue suggests a 'binary option' potential for substantial stock appreciation upon product launch.
Bear Case
The stock is risky due to zero revenue and consistent annual net losses over the past five years, with the most recent loss still standing at $-3.1M against a massive retained earnings deficit of $88.1M. With current assets of only $5.8M and no long-term assets or liabilities, the company lacks financial stability to weather prolonged development delays or potential regulatory rejections without further equity dilution.
About Bone Biologics Corp
Bone Biologics Corp (BBLG) is a clinical-stage biopharmaceutical company focused on developing innovative bone regeneration therapies for orthopedic applications. The company operates primarily in the United States, leveraging its pipeline of novel biologics to address unmet needs in spinal fusion and trauma care markets. With no current revenue, the firm relies heavily on financing activities to fund research and development efforts aimed at commercializing its proprietary technologies.
Analysis
Management Discussion
Recent financial performance shows the company narrowing its annual net loss from $-8.9M in 2023 to $-3.1M in 2025, indicating improved operational efficiency or reduced burn rate despite continued negative cash flow from operations of $-2.7M. The firm successfully converted a positive net change in cash of $2.0M through financing inflows that exceeded operating outflows, increasing total assets to $5.8M and ending cash reserves at $5.3M.
Industry Overview
The orthopedic bone regeneration industry is transitioning from traditional metallic implants to advanced biologics that promote faster healing and better integration with existing bone structures. This sector is characterized by high R&D costs, stringent FDA approval processes, and a growing market demand for solutions treating spinal fusion failures and complex trauma injuries.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Expenses | $3.7M | $9.4M | $4.2M | $3.2M |
| Operating Income | $-3.7M | $-9.4M | $-4.2M | $-3.2M |
| R&D | $1.6M | $6.9M | $2.1M | $1.1M |
| G&A | $2.1M | $2.5M | $2.1M | $2.2M |
| Stock-Based Comp | $266.6K | $152.6K | $188.8K | $256.4K |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Income | — | — | $55.7K | $122.0K |
| Pre-Tax Income | $-3.7M | $-9.4M | $-4.2M | $-3.2M |
| Income Tax | $-2.2M | $-479.6K | $-106.7K | $-134.9K |
| Continuing Ops | $-1.5M | $-8.9M | $-4.1M | $-3.1M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-1.5M | $-8.9M | $-4.1M | $-3.1M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-1.5M | $-8.9M | $-4.1M | $-3.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | — | $3.7M | $3.9M | $5.8M |
| Long-Term Assets | — | $0 | $0 | $0 |
| Total Assets | $8.5M | $3.7M | $3.9M | $5.8M |
| Current Liabilities | $2.5M | $831.4K | $377.7K | $418.6K |
| Long-Term Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.5M | $831.4K | $377.7K | $418.6K |
| Shareholders' Equity | $5.9M | $2.9M | $3.5M | $5.4M |
| Paid-In Capital | $77.9M | $83.8M | $88.5M | $93.5M |
| Retained Earnings | $-72.0M | $-80.9M | $-85.0M | $-88.1M |
| Total L&E | $8.5M | $3.7M | $3.9M | $5.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-1.5M | $-8.9M | $-4.1M | $-3.1M |
| Non-Cash Adjustments | $-3.8M | $-868.4K | $1.9K | $343.2K |
| Working Capital Changes | $1.7M | $261.2K | $-14.4K | $65.7K |
| Cash from Operations | $-3.6M | $-9.6M | $-4.1M | $-2.7M |
| Cash from Investing | $0 | $0 | $0 | $0 |
| Cash from Financing | $4.4M | $5.0M | $4.4M | $4.7M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $862.9K | $-4.5M | $298.6K | $2.0M |
| Beginning Cash | $6.7M | $7.5M | $3.0M | $3.3M |
| Ending Cash | $7.5M | $3.0M | $3.3M | $5.3M |
Frequently Asked Questions
How does Bone Biologics Corp make money?
The company currently operates as a single business segment focused on clinical-stage drug development, with all financial activity directed toward Research and Development expenses totaling $1.1M annually and General & Administrative costs of $2.2M to advance its pipeline.
What are the main risks for BBLG?
The company faces significant risk of dilution due to reliance on common share issuances of $4.4M to offset operating losses, lacks any revenue stream which creates high financial uncertainty, carries substantial accumulated retained earnings deficits of $88.1M requiring future profitability, and operates in a competitive market with high regulatory approval hurdles for novel biologics.
What is BBLG's competitive advantage?
Bone Biologics possesses proprietary biologic technologies designed for superior osteoinduction compared to standard implants, holds strategic partnerships to accelerate clinical progress, and maintains a lean operational structure with minimal long-term liabilities to preserve capital efficiency during the development phase.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.